Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR 155.00
+4.40 (2.92%)
At close: Jan 6, 2026
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,128,096
Profits / Employee
€180,266
Market Cap
23.66B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Biogen News
- 6 days ago - BIIB: Biogen's LEQEMBI Application Accepted in China - GuruFocus
- 6 days ago - Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China - GlobeNewsWire
- 9 days ago - Samsung Bioepis Co., Ltd.: Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe - Finanz Nachrichten
- 12 days ago - Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge - Seeking Alpha
- 18 days ago - Is Biogen Inc Gaining or Losing Market Support? - Benzinga
- 19 days ago - JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results - Nasdaq
- 20 days ago - Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment - GuruFocus
- 20 days ago - Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - Finanz Nachrichten